Claritas Pharmaceuticals, Inc. (CLAZF)
| Market Cap | 38.00 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.72M |
| Shares Out | 37.79M |
| EPS (ttm) | -0.13 |
| PE Ratio | 0.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,111 |
| Average Volume | 2,296 |
| Open | 0.0000 |
| Previous Close | 0.0000 |
| Day's Range | 0.0000 - 0.0000 |
| 52-Week Range | n/a |
| Beta | 32.64 |
| RSI | 45.58 |
| Earnings Date | n/a |
About Claritas Pharmaceuticals
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California. [Read more]
Financial Performance
Financial StatementsNews
Claritas Announces Approval from OTC to Up-List to OTCQB
SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to announce th...
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced that the ...